BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27443782)

  • 21. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
    Mohamed Z; Scott N; Nayagam S; Rwegasha J; Mbwambo J; Thursz MR; Brown AS; Hellard M; Lemoine M
    Int J Drug Policy; 2022 Jan; 99():103458. PubMed ID: 34624732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China.
    Wang Y; Shi JF; Wang L; Yan Y; Yao H; Dai M; Chen T; Qu C
    Int J Infect Dis; 2019 Jan; 78():130-139. PubMed ID: 30466898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Introduction of birth dose of hepatitis B virus vaccine to the immunization program in Ethiopia: an economic evaluation.
    Memirie ST; Desalegn H; Naizgi M; Nigus M; Taddesse L; Tadesse Y; Tessema F; Zelalem M; Girma T
    Cost Eff Resour Alloc; 2020; 18():23. PubMed ID: 32704237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.
    Hutton DW; Tan D; So SK; Brandeau ML
    Ann Intern Med; 2007 Oct; 147(7):460-9. PubMed ID: 17909207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.
    Mafirakureva N; Lim AG; Khalid GG; Aslam K; Campbell L; Zahid H; Van den Bergh R; Falq G; Fortas C; Wailly Y; Auat R; Donchuk D; Loarec A; Coast J; Vickerman P; Walker JG
    J Viral Hepat; 2021 Feb; 28(2):268-278. PubMed ID: 33051950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
    Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
    Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
    Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
    Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis.
    Rossi C; Schwartzman K; Oxlade O; Klein MB; Greenaway C
    PLoS One; 2013; 8(10):e78548. PubMed ID: 24205255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost-effectiveness of screening for chronic hepatitis B infection in the United States.
    Eckman MH; Kaiser TE; Sherman KE
    Clin Infect Dis; 2011 Jun; 52(11):1294-306. PubMed ID: 21540206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Universal Hepatitis B Antibody Screening and Vaccination in Pregnancy: A Cost-Effectiveness Analysis.
    Prabhu M; Susich MK; Packer CH; Hersch AR; Riley LE; Caughey AB
    Obstet Gynecol; 2022 Mar; 139(3):357-367. PubMed ID: 35115449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
    Kim HL; Kim GA; Park JA; Kang HR; Lee EK; Lim YS
    Gut; 2021 Nov; 70(11):2172-2182. PubMed ID: 33239344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NéoVac Study).
    Gosset A; Diallo MY; Betsem E; Schaeffer L; Meda N; Vray M; Sombie R; Shimakawa Y; Boyer S
    Vaccine; 2021 Jul; 39(33):4659-4670. PubMed ID: 34238606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union.
    Pereira A
    Transfusion; 2003 Feb; 43(2):192-201. PubMed ID: 12559015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms.
    Crespo J; Esteban R; Torres C; Oyagüez I; Casado MÁ; Buti M
    Rev Esp Enferm Dig; 2017 Sep; 109(9):619-626. PubMed ID: 28648087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenofovir disoproxil fumarate in pregnancy for prevention of mother to child transmission of hepatitis B in a rural setting on the Thailand-Myanmar border: a cost-effectiveness analysis.
    Bierhoff M; Angkurawaranon C; Rijken MJ; Sriprawa K; Kobphan P; Nosten FN; van Vugt M; McGready R; Devine A
    BMC Pregnancy Childbirth; 2021 Feb; 21(1):157. PubMed ID: 33618698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.
    Jia Y; Li L; Cui F; Zhang D; Zhang G; Wang F; Gong X; Zheng H; Wu Z; Miao N; Sun X; Zhang L; Lv J; Yang F
    Hum Vaccin Immunother; 2014; 10(10):2983-91. PubMed ID: 25483678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United Kingdom.
    Williams J; Vickerman P; Douthwaite S; Nebbia G; Hunter L; Wong T; Ruf M; Miners A
    Value Health; 2020 Aug; 23(8):1003-1011. PubMed ID: 32828211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
    Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
    J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.